Clinical trial · Observational
Family History and Cancer Risk Study
Improving Identification and Healthcare for Patients With Inherited Cancer Syndromes: Evidence-based EMR Implementation Using a Web-based Computer Platform
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators from Vanderbilt University Medical Center (VUMC), Duke University, and Meharry Medical College (MMC) are collaborating on a family health history study to deploy a family health history (FHH) platform, MeTree. Recruited participants will complete surveys, the MeTree questionnaire, and MeTree will determine the participant's cancer risk based on current guidelines. The study team will offer genetic counseling to high-risk participants. Investigators will track participant outcomes and behaviors from the use of MeTree to determine the efficiency of the use of MeTree compared to completion of pedigrees in clinic.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Comparative Effectiveness Research | — | UNRESOLVED | — |
| Neoplastic Syndromes, Hereditary | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- MeTree Completion (REACH)
- timeFrame
- From enrollment to study completion (up to 3 years)
- description
- Proportion of participants sent a MeTree link who complete the MeTree family health history questionnaire, defined by generation of a MeTree risk report. Engagement steps (link clicked, account created) will be summarized descriptively. 95% confidence intervals will be reported using the Wilson method; subgroup comparisons by site and demographics will be exploratory.
Secondary outcomes (2)
- measure
- EHR-based Identification for High Risk of Hereditary Cancer (Effectiveness)
- timeFrame
- Assessed at two time points: baseline (pre-MeTree, using all available prior EHR history) and 12 months after MeTree completion.
- description
- Billing code based identification of personal or family history indicators of hereditary cancer
- measure
- Genetic Counseling Appointment Lengths
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Receiving care at sites included in study * Able to read and communicate in English * Willing to use the Internet * Currently enrolled in the patient portal, or willing to enroll (VUMC-specific) Exclusion Criteria: * Non-study site patient * Diagnosed with a terminal illness * Unable to speak/read English * Unable/unwilling to use the Internet * Previous genetic testing and/or counseling from the VUMC Hereditary Cancer Clinic
References
Publications (2)
- BACKGROUNDMittendorf KF, Bland HT, Andujar J, Celaya-Cobbs N, Edwards C, Gerhart M, Hooker G, Hubert M, Jones SH, Marshall DR, Myers RA, Pratap S, Rosenbloom ST, Sadeghpour A, Wu RR, Orlando LA, Wiesner GL. Family history and cancer risk study (FOREST): A clinical trial assessing electronic patient-directed family history input for identifying patients at risk of hereditary cancer. Contemp Clin Trials. 2025 Jan;148:107714. doi: 10.1016/j.cct.2024.107714. Epub 2024 Oct 10. PMID 39395532
- DERIVEDOrlando LA, Mittendorf KF, Bihlmeyer NA, Bland HT, Myers RA, Pratap S, Celaya-Cobbs N, Andujar J, Gerhart M, Sadeghpour A, Hooker G, Wu RR, Marshall DR, Edwards C, Frederickson KL, Leegon J, Jones SH, Rosenbloom ST, Peterson JF, Wiesner GL. Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform: A Nonrandomized Clinical Trial. JAMA Netw Open. 2026 Apr 1;9(4):e269816. doi: 10.1001/jamanetworkopen.2026.9816. PMID 42054024